Max Shapiro, MD
Gastroenterology · Atlanta, GANPI 1770768780
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,562 of the $12,243 with a category attached, or 86.3%. It is spread thinly across 33 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 573 payments — averaging $21.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$833
- Pfizer$812
- Lilly USA, LLC$678
- plus $4K from 27 others
Across 15 payments — averaging $7601.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$114K
What the payments were for
- Consulting fees$1,57213%
- Food & beverage$10,56286%
- Education$901%
- Gifts$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 24 | $2,162 |
| AbbVie(2 entities) | 117 | $2,035 |
| Takeda Pharmaceuticals U.S.A., Inc. | 91 | $1,687 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $833 |
| Pfizer | 56 | $812 |
| Lilly USA, LLC | 31 | $678 |
| Johnson & Johnson | 41 | $660 |
| Regeneron Healthcare Solutions, Inc. | 21 | $567 |
| Bristol Myers Squibb | 30 | $500 |
| Madrigal Pharmaceuticals | 11 | $338 |
| Intercept Pharmaceuticals, Inc. | 12 | $239 |
| Organon | 13 | $218 |
| Ipsen Biopharmaceuticals, Inc | 9 | $198 |
| Merck | 7 | $146 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| QOL Medical, LLC | 5 | $113 |
| Braintree Laboratories, Inc. | 7 | $112 |
| Phathom Pharmaceuticals, Inc. | 7 | $108 |
| Ironwood Pharmaceuticals, Inc | 7 | $107 |
| Ferring Pharmaceuticals Inc. | 7 | $105 |
| Celltrion USA Inc. | 4 | $94 |
| Medtronic | 2 | $59 |
| Aimmune Therapeutics, Inc. | 3 | $54 |
| Ardelyx, Inc. | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Blueprint Medicines Corporation | 1 | $43 |
| Gilead | 2 | $42 |
| Redhill Biopharma Inc. | 2 | $26 |
| Vivus LLC | 1 | $20 |
| Medline Industries LP | 1 | $17 |
| Olympus America Inc. | 1 | $14 |
| Micro-tech Endoscopy USA, Inc. | 1 | $13 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,243 in reported general payments places this provider in the 85th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GattexTeduglutide | 11 | $492,805 |
| LinzessLinaclotide | 32 | $35,000 |
| Mesalamine | 23 | $20,800 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 120 | $7,981 |
| DexilantDexlansoprazole | 12 | $3,609 |
| Colesevelam Hcl | 22 | $2,839 |
| Famotidine | 75 | $1,099 |
| Omeprazole | 99 | $991 |
| Budesonide DrBudesonide | 15 | $973 |
| Lansoprazole | 16 | $910 |
| Pantoprazole Sodium | 92 | $869 |
| Rabeprazole Sodium | 23 | $667 |
| Esomeprazole Magnesium | 16 | $637 |
| Promethazine Hcl | 11 | $170 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gattex, Dexilant | $1,687 | $496,41423 claims |
| AbbVieLinzess | $2,035 | $35,00032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Atlanta
- Nitin GuptaAtlanta$1.1M
- Cynthia RudertAtlanta$720K
- Douglas WolfAtlanta$668K
- Kavita KongaraAtlanta$492K
- Girish AnandAtlanta$425K
- Roshan ShresthaAtlanta$317K
- Hetal KarsanAtlanta$314K
- Marc SonenshineAtlanta$201K
- Julia LiuAtlanta$163K
- Huiming HonAtlanta$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.